Expression of c-erbB3 protein in primary breast carcinomas
about
Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomasSuppression of cell growth and invasion by miR-205 in breast cancerThe ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferationNeuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labellingEssential function for ErbB3 in breast cancer proliferationDual activation of pathways regulated by steroid receptors and peptide growth factors in primary prostate cancer revealed by Factor Analysis of microarray data.Targeting of erbB3 receptor to overcome resistance in cancer treatmentQuantification of HER family receptors in breast cancerRegulation of ERBB3/HER3 signaling in cancerEpithelial-mesenchymal transition markers and HER3 expression are predictors of elisidepsin treatment response in breast and pancreatic cancer cell linesErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactationCorrelation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancerPseudokinases: update on their functions and evaluation as new drug targets.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors.E3 ubiquitin ligases in ErbB receptor quantity control.The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.The epidermal growth factor receptor family in breast cancer.Targeting miR-205 in breast cancer.Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cellsInhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.Association between AgNORs and Immunohistochemical Expression of ER, PR, HER2/neu, and p53 in Breast CarcinomaThe anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition.Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines.Dysregulation of HER2/HER3 signaling axis in Epstein-Barr virus-infected breast carcinoma cells.Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cellsActivated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapyPotential use of humanized antibodies in the treatment of breast cancer.ErbB receptor negative regulatory mechanisms: implications in cancer.HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.Targeting HER proteins in cancer therapy and the role of the non-target HER3.A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.
P2860
Q21144348-22B90EAA-7E0B-4492-9ECF-0C241630AD01Q24647586-B293BD60-DE99-4AE2-BD9B-0EAD73BF2357Q24678674-8A97726E-FB33-44BD-8D41-4BB536503FCBQ24681497-513D59E3-8753-4FF7-809D-CFC3BA8BC176Q24794988-287728FD-9C75-44D4-AF29-04B85D418189Q24795054-62405C43-CB4E-4D39-B199-782B720E0DACQ24817218-10CA2539-230C-4BE1-9D56-DAFD65404F06Q26864668-2248C42C-3229-41A8-8421-BB919D4D4957Q27015506-A146ACC8-6362-4C0D-B7CE-E22D15534F68Q27024334-BC5F879D-31A4-440E-A436-51491A112CC6Q28484892-A67D543D-BEB4-4799-87E9-2694F3CFB66BQ28594099-5415C7F4-4D89-4702-9A08-459D927CA35AQ28728701-D7BFD693-CB03-4112-B0D5-A7CA7D74AFF5Q30397636-09979FF5-D696-4E91-A64C-268470853449Q34103963-F40E8387-EA1D-4B15-95BB-4B7F83382C8EQ34121278-C871541A-7057-427C-93DE-A7E8D71AD709Q34349106-D267524F-2890-46C5-80D8-65C875AB2FAEQ34349389-1CF652DC-47A8-4CA8-BEBB-411CE49DFC04Q34363400-638517F2-DCD3-4C09-89DC-F9856E29A679Q35008487-82D17516-58C1-4A6E-8D45-E7D998D8D385Q35071151-141F4AFE-812A-4268-AA0E-14D28D4E974FQ35157356-606CBFBA-CE6E-4395-80BE-0954D3F30ADBQ35157568-295BC33E-E0F1-4B12-BA0F-FDDE6BC21897Q35201923-5886C97C-5C0B-4017-8523-51C4CCE2FCA1Q35234347-0441B146-FD34-4DCA-8F19-C83034B205E6Q35504371-24D49701-20F9-404F-B9CC-16A85F413903Q35571641-5B5AB9E7-A52E-4324-97EA-26C8B9CF8C5AQ35586732-7B7CFD1F-6287-4EDF-A350-B6BB73AB7085Q35683561-5569D8C5-5FF5-42D2-B56F-4E00E9969956Q35857669-A6C68901-FCCF-4687-933A-775E0FAA30E6Q36025400-FA1AD505-6E6E-42CC-98D5-02B873C05153Q36223407-32BE89AB-EF21-4BE3-84A1-97DB9229F3EFQ36532110-B8481C46-5E20-45E2-8D29-7B798A9A5D22Q36545883-6C29689F-06E5-48E6-9191-67F9F295EEC7Q36615002-D4797C3C-B05A-4CEF-998F-B844033937FDQ36670915-188E2ABC-E7CE-4878-8F96-2BBA95E6CEC6Q36696088-F96BEF0B-C6ED-44A5-B042-B062F7B8FACDQ36780754-58D42F29-7FFB-46C2-93E1-611679322CB4Q36898642-BBC1329A-B79A-4BBE-B3CA-D47EABEBB4BCQ36925694-68743BCA-4F62-4044-A452-3BDF0F994733
P2860
Expression of c-erbB3 protein in primary breast carcinomas
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Expression of c-erbB3 protein in primary breast carcinomas
@ast
Expression of c-erbB3 protein in primary breast carcinomas
@en
type
label
Expression of c-erbB3 protein in primary breast carcinomas
@ast
Expression of c-erbB3 protein in primary breast carcinomas
@en
prefLabel
Expression of c-erbB3 protein in primary breast carcinomas
@ast
Expression of c-erbB3 protein in primary breast carcinomas
@en
P2093
P2860
P356
P1476
Expression of c-erbB3 protein in primary breast carcinomas
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1998.689
P407
P577
1998-11-01T00:00:00Z
P5875
P6179
1033425444